Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires

12. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Number of Hedge Fund Holders In Q3 2024: 44

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a small biotechnology company that develops and sells drugs for neuropsychiatric illnesses. It is a loss-making entity but does generate revenue through medications such as CAPLYTA that help patients with schizophrenia and bipolar depression. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s shares are up by a strong 49% year-to-date despite the fact that its product portfolio has remained unchanged. The optimism is due to JNJ’s interest in acquiring the firm for a cool $14.6 billion price tag. Cramer, however, is wary of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s product portfolio:

“Because Bristol-Myers currently has Cobenfy, that’s just been approved, FDA, exactly for some of these indications that Intra-Cellular is supposed to be good for. Their drug has been [inaudible], this is Caplyta, since 2019, and has not curried the favor of psychiatrists so far. So I wanna find out how good this drug really is versus Cobenfy.

“But I want to hear what Bristol says, because Bristol’s got the one that everybody is buzzing about. Which is Cobenfy. Not what Intra-Cellular has.

“And I really want to know, I mean I know that when the FDA approved Cobenfy for Bristol-Myers, it was a really big deal. Because they were regarded as the first in thirty years. Now we’re discovering that hold it, just a second, Intra-Cellular had something. Well if they had something, why was Bristol saying that this is the first in thirty years for these indications? I think we have to dig deeper in this.”